Last reviewed · How we verify

Placebo lanreotide

University Hospital, Limoges · Phase 3 active Small molecule

Placebo lanreotide is a Somatostatin analogue Small molecule drug developed by University Hospital, Limoges. It is currently in Phase 3 development for Acromegaly, Gastrointestinal neuroendocrine tumors.

Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones.

Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones. Used for Acromegaly, Gastrointestinal neuroendocrine tumors.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo lanreotide
SponsorUniversity Hospital, Limoges
Drug classSomatostatin analogue
TargetSomatostatin receptor
ModalitySmall molecule
Therapeutic areaEndocrinology
PhasePhase 3

Mechanism of action

It works by binding to somatostatin receptors on the surface of pituitary cells, which reduces the secretion of growth hormone and other hormones. This can help to reduce symptoms associated with acromegaly and other conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo lanreotide

What is Placebo lanreotide?

Placebo lanreotide is a Somatostatin analogue drug developed by University Hospital, Limoges, indicated for Acromegaly, Gastrointestinal neuroendocrine tumors.

How does Placebo lanreotide work?

Lanreotide is a somatostatin analogue that inhibits the release of growth hormone and other hormones.

What is Placebo lanreotide used for?

Placebo lanreotide is indicated for Acromegaly, Gastrointestinal neuroendocrine tumors.

Who makes Placebo lanreotide?

Placebo lanreotide is developed by University Hospital, Limoges (see full University Hospital, Limoges pipeline at /company/university-hospital-limoges).

What drug class is Placebo lanreotide in?

Placebo lanreotide belongs to the Somatostatin analogue class. See all Somatostatin analogue drugs at /class/somatostatin-analogue.

What development phase is Placebo lanreotide in?

Placebo lanreotide is in Phase 3.

What are the side effects of Placebo lanreotide?

Common side effects of Placebo lanreotide include Diarrhea, Nausea, Abdominal pain, Injection site reaction.

What does Placebo lanreotide target?

Placebo lanreotide targets Somatostatin receptor and is a Somatostatin analogue.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing